
|Videos|April 28, 2022
Newly Diagnosed Multiple Myeloma: The MASTER and GMMG-HD7 Trials
A review of the study design and results of two clinical trials researching quadruplet therapies for newly diagnosed multiple myeloma presented at ASH 2021.
Advertisement
Episodes in this series

Advertisement
Related to this article

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.

In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Advertisement
Advertisement
Trending on CancerNetwork
1
Matching Neoadjuvant Therapy to Tumor Genomics in High-Risk Prostate Cancer
2
Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific Antibodies
3
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
4
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
5





